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To identify the risk factors for cervical intraepithelial neoplasia (CIN), we reanalysed the data from our previous case–control study
by adjusting for human papillomavirus (HPV) antibodies. Unlike our previous study based only on HPV DNA, smoking and Chlamydia
trachomatis infection were revealed as significant risk factors for CIN after adjustment for HPV antibodies.
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Infections by oncogenic human papillomaviruses (HPVs) are
established as a major risk factor for cervical intraepithelial
neoplasia (CIN) and invasive cervical cancer (ICC). However, only
a fraction of infected women develop cervical cancer, suggesting
the involvement of additional cofactors in cervical carcinogenesis.
In numerous case–control studies various epidemiological factors
have been suggested as relevant to CIN and ICC, although the
results from these studies have not been entirely consistent
(Schiffman and Brinton, 1995). In epidemiological studies of risk
factors for CIN and ICC, it is of great importance to allow for the
strong effect of HPV infections. To determine HPV exposure
among cases and controls, most studies have used HPV DNA
testing, while recent studies have employed HPV capsid serology.
However, it has not been determined whether the different
measurements of HPV exposure can affect conclusions from
case–control studies.
To address this issue, we reanalysed the data from our previous
case–control study of CIN by adjusting for HPV DNA and
antibodies.
MATERIALS AND METHODS
The present study was conducted on women who previously
participated in a Japanese case–control study of CIN. The details
about this case–control study have been provided elsewhere
(Yoshikawa et al, 1999). Among a total of 167 pairs, serum samples
from 26 cases and 58 controls were not available for HPV capsid
serology. Therefore, the present analysis was restricted to 250
subjects consisting of 141 cases (80 CIN I, 34 CIN II and 27 CIN
III) and 109 controls that were tested for both cervical HPV DNA
and serum HPV antibodies. The distributions of study variables in
the excluded/included cases and controls were similar. We
examined HPV DNA in cervical samples by polymerase chain
reaction (PCR) using consensus primers for the HPV L1 region
(Yoshikawa et al, 1999). Detection of IgG antibodies to HPV16, 52
and 58, the most frequently detected HPV types in Japan, was
performed by enzyme-linked immunosorbent assay (ELISA) using
purified L1-capsids (virus-like particles (VLPs)) as antigens
(Matsumoto et al, 2003). In addition, the level of IgG antibodies
to Chlamydia trachomatis was determined by using an enzyme
immunoassay (EIA) kit (Thermo Labsystems, Vantaa, Finland)
that does not detect antibody to Chlamydia pneumoniae. The
adjusted odds ratios (ORs) and 95% confidence intervals (CIs)
were estimated by a logistic regression analysis. The analysis was
carried out using JMP 4.0J statistics package (SAS Institute, Cary,
NC, USA). The P-values obtained in all tests were considered
significant at o0.05.
RESULTS
Human papillomavirus status among cases and controls was
determined by using HPV DNA testing and HPV capsid serology
(Table 1). We reconfirmed that HPV DNA positivity and HPV
seropositivity were strongly associated with CIN development
(Po0.0001 and ¼0.0002, respectively), although the relative risk
for CIN was considerably different between HPV DNA positive and
seropositive women (17.9 and 2.7, respectively) (Table 2). The
estimated risks for CIN development in relation to various
epidemiological factors are shown in Table 3. In the present
study, the adjusted analysis for HPV DNA alone gave the same
results as our previous study (Yoshikawa et al, 1999). Marriage,
multiparity and age at first pregnancy were found to be significant
risk factors for CIN development in the crude and adjusted
analyses. Sexual behaviour, including age at first intercourse and
lifetime number of sexual partners, was significantly associated
with an increased risk of CIN in the crude analysis, but the
significance disappeared in both adjusted analyses. Current Received 2 April 2003; revised 30 June 2003; accepted 2 July 2003
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cofactors for CIN development after adjusting for HPV antibodies,
although not after adjusting for HPV DNA. We found no association
between the use of oral contraceptives (OC) and CIN development
because of the low prevalence of OC users among study subjects.
The effect of smoking on CIN development did not appear to vary
between HPV-positive and HPV-negative subjects, while the effect
of C. trachomatis infection was stronger among the former.
DISCUSSION
With regard to smoking and C. trachomatis infection, the analysis
adjusted for HPV antibodies gave different results from the
analysis adjusted for HPV DNA. One explanation for this
difference is that the antibody adjustment may reflect residual
Table 2 Human papillomavirus infections and the estimated risks for
CIN
Case (n¼141) Control (n¼109) OR (95% CI)
a
HPV DNA
Negative 36 (26%) 93 (85%) 1.0
Positive 105 (74%) 16 (15%) 17.9 (9.5–36.0)
HPV antibodies
b
Negative 65 (46%) 76 (70%) 1.0
Positive 76 (54%) 33 (30%) 2.7 (1.6–4.6)
aodds ratios and 95% confidence intervals adjusted for age.
bIgG antibodies to any
type of HPV16/52/58 L1-capsids.
Table 1 Human papillomavirus status among cases and controls
HPV status
DNA Antibodies
a Case (n¼141) Control (n¼109)
— — 21 (15%) 65 (60%)
— + 15 (11%) 28 (26%)
+ — 44 (31%) 11 (10%)
+ + 61 (43%) 5 (4%)
aIgG antibodies to any type of HPV16/52/58 L1-capsids.
Table 3 Estimated risks for CIN associated with epidemiological cofactors
Variables Number of
cases/controls
Crude OR
a
(95% CI)
b
OR adjusted for
HPV DNA and Age
(95% CI)
OR adjusted for
HPV Ab
c and Age
(95% CI)
Marital status
Never married 8/14 1.0 1.0 1.0
Separated/widowed 12/11 1.9 (0.6–6.3) 0.5 (0.1–2.7) 1.3 (0.3–5.1)
Married 121/84 2.5 (1.0–6.1) 3.9 (1.2–13.3) 2.8 (1.1–7.4)
P¼0.04 P¼0.04 P¼0.04
Parity
0 12/18 1.0 1.0 1.0
1–2 78/66 1.7 (0.8–3.9) 2.0 (0.7–5.9) 1.3 (0.6–2.9)
3+ 50/24 3.1 (1.3–7.4) 4.7 (1.4–15.7) 3.5 (1.4–9.1)
P for trend¼0.01 P¼0.01 P¼0.03
Age at first pregnancy (years)
–23 63/26 2.0 (1.1–3.7) 3.5 (1.4–9.2) 3.5 (1.6–7.9)
24–26 37/38 1.0 1.0 1.0
27+ 31/26 1.1 (0.6–2.1) 0.9 (0.3–2.6) 0.7 (0.3–1.7)
P for trend¼0.03 P¼0.01 P¼0.01
Cigarette smoking
Never 94/78 1.0 1.0 1.0
Past 13/14 0.8 (0.3–1.7) 0.3 (0.1–1.1) 0.4 (0.1–1.2)
Current 34/17 1.7 (0.9–3.2) 3.0 (0.9–9.9) 3.2 (1.2–8.8)
P¼0.13 P¼0.09 P¼0.04
IgG antibody to C. trachomatis
Negative 109/98 1.0 1.0 1.0
Positive 32/11 2.6 (1.3–5.4) 1.7 (0.7–4.3) 2.7 (1.3–6.0)
P¼0.01 P¼0.26 P¼0.01
Use of oral contraceptives
Never 130/98 1.0 1.0 1.0
Ever 7/9 0.6 (0.2–1.6) 0.9 (0.3–2.8) 0.6 (0.2–1.4)
P¼0.30 P¼0.94 P¼0.18
Age at first intercourse (years)
–23 111/74 1.9 (1.1–3.4) 1.8 (0.9–3.8) 1.8 (0.9–3.3)
24+ 27/34 1.0 1.0 1.0
P¼0.03 P¼0.14 P¼0.10
Lifetime number of sexual partners
0–1 65/64 1.0 1.0 1.0
2–3 42/28 1.5 (0.8–2.7) 0.7 (0.2–1.8) 1.1 (0.5–2.4)
4+ 34/17 2.0 (1.0–3.9) 2.2 (0.7–7.0) 2.0 (0.8–5.3)
P for trend¼0.04 P¼0.41 P¼0.15
aOdds ratios.
b95% confidence intervals.
cIgG antibodies to any type of HPV16/52/58 L1-capsids.
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seropositive for HPV16/52/58 due to the limited sensitivity and
high type-specificity of HPV capsid serology (Matsumoto et al,
2003). Another reasonable explanation is that smoking and C.
trachomatis infection may be significant cofactors associated with
persistent HPV infections. In controls, HPV DNA positivity was
much lower than seropositivity (15 vs 30%, respectively). Since
HPV DNA testing at a single time point cannot identify past
infections, the analysis based on HPV DNA may miss cofactors
determining whether HPV infection is cleared or becomes
persistent. In fact, a very recent study reported that smoking is
associated with a reduced probability of clearing oncogenic HPV
infections (Giuliano et al, 2002). Associations of smoking and C.
trachomatis infection with persistent HPV infections may be
supported by several studies suggesting the modulation of host
immunity by smoking (Barton et al, 1988) and chlamydial
infection (Zhong et al, 1999).
Although the DNA adjustment enhanced the CIN risk among
current smokers as well as the antibody adjustment, the
association of smoking with an increased risk of CIN was not
statistically significant in the DNA-based analysis. This may be due
to the small numbers in the statistical analysis.
Unlike our previous study based on HPV DNA (Yoshikawa et al,
1999), the present study has shown that smoking and
C. trachomatis infection are significant cofactors for CIN
development after adjustment for HPV antibodies. Simi-
larly, associations of smoking and C. trachomatis infection
with cervical neoplasia have been consistent in case–control
studies employing HPV capsid serology (Dillner et al, 1997;
Olsen et al, 1998; Kjellberg et al, 2000; Koskela et al, 2000;
Anttila et al, 2002), but inconsistent in HPV DNA-based studies
(Schiffman et al, 1993; de Sanjose ´ et al, 1994; Eluf-Neto et al, 1994;
Olsen et al, 1995; Ferrera et al, 1997). Our observation
suggests that epidemiological studies relying on a single
assessment of HPV status should be interpreted with caution. To
fully evaluate the role of epidemiological cofactors in HPV-related
carcinogenesis, allowance for both HPV DNA and antibodies may
be necessary.
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